RT Conference Proceedings
T1 Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
A1 Hernando, J.
A1 Manzano, J. L.
A1 Teule, A.
A1 Lopez, C.
A1 Garcia-Carbonero, R.
A1 Benavent Vinuales, M.
A1 Custodio, A.
A1 Cubillo, A.
A1 Alonso, V.
A1 Alonso-Gordoa, T.
A1 Carmona-Bayonas, A.
A1 Crespo, G.
A1 Blanco, M.
A1 Jimenez-Fonseca, P.
A1 Viudez, A.
A1 La Casta, A.
A1 Sevilla, I.
A1 Llanos, M.
A1 Segura, A.
A1 Capdevila, J.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27027
UL https://hdl.handle.net/10668/27027
LA en
DS RISalud
RD Apr 6, 2025